Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea

Cost Effectiveness and Resource Allocation : C/E
Donghoon LeeSang Min Park

Abstract

In Korea, hepatitis B virus (HBV) infection accounts for approximately 65-75% of HBV-related diseases, such as chronic hepatitis and liver cancer, and mother-to-child transmission is presumed to be a major source of the infection. To tackle this issue, the Korean government launched the national Perinatal Hepatitis B Prevention Program (PHBPP) in 2002. This study analyzed the cost-effectiveness of the PHBPP with antiviral prophylaxis compared with the current PHBPP and/or universal vaccination, as well as identified the optimal strategy to eliminate mother-to-child transmission of HBV in Korea. A decision tree model with the Markov process was developed and simulated over the lifetime of a birth cohort in Korea during the year 2014. The current PHBPP providing HBV vaccine and hepatitis B immune globulin to neonates born to HBV positive mothers was compared against two other strategies, universal vaccination of HBV and PHBPP with antiviral prophylaxis, with respect to their costs and health outcomes. The Korean National Health Insurance database was investigated to estimate the costs of HBV-related diseases and utilization of health resources. Costs were assessed from the health care system perspective and converted to 2014 US d...Continue Reading

References

Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Aug 23, 1993·Proceedings. Biological Sciences·W J EdmundsH C Whittle
Oct 1, 1996·Epidemiology and Infection·W J EdmundsA J Hall
Jan 6, 1999·JAMA : the Journal of the American Medical Association·J B WongS G Pauker
Jan 12, 2001·Journal of Epidemiology and Community Health·L Bonneux, E Birnie
Aug 20, 2005·BMJ : British Medical Journal·Werner B F BrouwerFrans F H Rutten
Nov 27, 2007·Bulletin of the World Health Organization·Sun-Young KimSue J Goldie
Apr 4, 2008·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Eun-Young Bae
Feb 20, 2009·Oncology·Soo Ryang KimUNKNOWN Organizing Committee of Japan-Korea Liver Symposium
Apr 1, 2009·Digestive Diseases and Sciences·Bong-Min YangSangjin Shin
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian J McMahon
May 6, 2009·The Medical Journal of Australia·Elke WisemanMiriam T Levy
Nov 15, 2011·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Calvin Q PanMyron J Tong
Feb 9, 2012·The Korean Journal of Hepatology·Sunmi LeeKyung Rae Hyun
Feb 7, 2013·Vaccine·Sandy Qiuying LuRichard Fielding
Jan 21, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sean D SullivanWen-Yi Shau
Oct 29, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lin FanTrudy V Murphy
Nov 14, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert S BrownKhaled Mohammed
Oct 25, 2016·Journal of Korean Medical Science·Jihyun YoonSeok Jun Yoon
Oct 31, 2016·International Journal of Epidemiology·Sang Cheol SeongSoon Ae Shin

❮ Previous
Next ❯

Citations

Feb 13, 2021·Obstetrics and Gynecology Clinics of North America·Sarah C Rogan, Richard H Beigi
Sep 25, 2020·Journal of Hepatology·Jessica HowellMargaret Hellard
May 9, 2021·Vaccine·Cynthia Raissa Tamandjou TchuemSusan Cleary

❮ Previous
Next ❯

Software Mentioned

TreeAge Pro
TreeAge

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.